Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,060.86 USD

1,060.86
452,590

+5.29 (0.50%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $1,065.30 +4.44 (0.42%) 9:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQEW

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.

Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq

by Zacks Equity Research

Alimera's (ALIM) stock jumps 19.4% after the company inks a deal with Eyepoint to acquire additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline

by Zacks Equity Research

Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.

Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.

Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.

Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Regeneron (REGN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More

by Kinjel Shah

Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.

Why Earnings Season Could Be Great for Regeneron (REGN)

by Zacks Equity Research

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

LGND vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

LGND vs. REGN: Which Stock Is the Better Value Option?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Regeneron (REGN) closed at $792.29, marking a +1.84% move from the previous day.

Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong

by Zacks Equity Research

Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche (RHHBY) Q1 Revenues Decline on Lower COVID-19 Test Sales

by Zacks Equity Research

Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.

Ekta Bagri headshot

4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates

by Ekta Bagri

We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Regeneron (REGN) closed at $800.73, marking a +0.33% move from the previous day.